Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Lasers in Medical Science
Published in: Lasers in Medical Science 1/2023

01-12-2023 | Photodynamic Therapy | Original Article

Immunohistochemistry technique for effect of gold nanoparticles, laser, and photodynamic therapy on FoxP1 level in infected mice with mammary adenocarcinoma

Authors: Sumaiah I. Hussein, Amal Y. Al-Yasiri, Heba F. Hassan, Basim M. Kashman, Rasha A. Azeez

Published in: Lasers in Medical Science | Issue 1/2023

Login to get access

Abstract

The current study was performed to investigate the treatment of tumors with gold nanoparticles, laser, and photodynamic therapy (PDT) by using an immunohistochemistry method and to investigate the expression of FOXP1 in infected mice with mammary adenocarcinoma whether it can be used as an indicator to estimate the recovery of tissues from cancer disease. Twenty-five albino female mice were used in this research; they were divided into five groups, four groups were infected with mammary adenocarcinoma, and then three of them were treated with gold nanoparticles, laser, and PDT, respectively, while the fourth group was left without any treatment and represents the positive control, and the fifth group (normal mice) represents the negative control. Tissue sections were taken from different groups of mice in order to estimate FOXP1 expression in infected mice by using an immunohistochemistry assay. FOXP1 expression was higher in the tumor and kidney tissues of the mice treated with PDT than that in mice treated with either gold nanoparticles or laser alone. Also, in the group of mice treated with laser, FOXP1 expression was higher than the expression in mice which were treated with gold nanoparticles but lower than that in mice which were treated with PDT. FOXP1 can be used as a biomarker for the prognosis outcome of breast and other solid tumors, as well as it considers a key tumor suppressor. PDT is the best choice to treat cancer in comparison to using either gold nanoparticles or the laser separately.
Literature
1.
2.
Coffer PJ, Burgering BM (2004) Forkhead-box transcription factors and their role in the immune system. Nat Rev Immunol 4:889CrossRefPubMed
3.
Carlsson P, Mahlapuu M (2002) Forkhead transcription factors: key players in development and metabolism. Dev Biol 250:1–23CrossRefPubMed
4.
Adams H, Tzankov A, Lugli A et al (2009) New time-dependent approach to analyse the prognostic significance of immunohistochemical biomarkers in colon cancer and diffuse large B-cell lymphoma. J Clin Pathol 62:986–997CrossRefPubMed
5.
Hoeller S, Schneider A, Haralambieva E et al (2010) FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structuralaberrations at 3p14.1. Histopathol 57:73–80CrossRef
6.
Giatromanolaki A, Koukourakis MI, Sivridis E et al (2006) Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1alpha expression. Mod Pathol 19:9–16CrossRefPubMed
7.
Takayama K, Horie-Inoue K, Ikeda K et al (2008) FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells. Biochem Biophys Res Commun 374:388–393CrossRefPubMed
8.
Toma MI, Weber T, Meinhardt M et al (2011) Expression of the Forkhead transcription factor FOXP1 is associated with tumor grade and Ki67 expression in clear cell renal cell carcinoma. Cancer Invest 29:123–129CrossRefPubMed
9.
Bates GJ, Fox SB, Han C et al (2008) Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas. Breast Cancer Res Treat 111:453–459CrossRefPubMed
10.
Brown PJ, Wong KK, Felce SL et al (2016) FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas. Leukemia 30:605–616CrossRefPubMed
11.
Flori M, Schmid CA, Sumrall ET (2016) The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling. Blood 127:1438–1448CrossRefPubMed
12.
13.
Takayama K, Suzuki T, Tsutsumi S et al (2014) Integrative analysis of FOXP1 function reveals a tumor-suppressive effect in prostate cancer. Mol Endocrinol 28:2012–2024CrossRefPubMedPubMedCentral
14.
Xiao J, He B, Zou Y, Chen X, Lu X, Xie M et al (2016) Prognostic value of decreased FOXP1 protein expression in various tumors: a systematic review and meta-analysis. Sci Rep 6:30437CrossRefPubMedPubMedCentral
15.
Brown SD, Nativo P, Smith JA et al (2010) Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J Am Chem Soc 132(13):4678–4684CrossRefPubMedPubMedCentral
16.
Rada AG, Abbasi H, Afzalib MH (2011) Gold nanoparticles: synthesising, characterizing and reviewing novel application in recent years. Phys Procedia 22:203–208CrossRef
17.
18.
Al-Shaabani MJ, Turki AM, Al-Mathkhury HJ (2020) The antibiofilm efficacy of gold nanoparticles against Acinetobacter baumannii. Iraqi J Sci 61(4):749–753CrossRef
19.
Correia JH, Rodrigues JA, Pimenta S, Dong T, Yang Z (2021) Photodynamic therapy review: principles, photosensitizers, applications, and future directions. Pharm 13(9):1332
20.
Khashman BM (2017) Study the oncomodulation potential of human cytomegalovirus and its correlation with TGF-β1 in a group of Iraqi patients with OSCC. Int J Sci Res 6(5):2196–2200
21.
Al-Zwaini YK, Al-Mugdadi SF, Abbas WA (2022) Detection of FOXP-3 expression in a sample of Iraqi cervical cancer patients using immunohistochemistry technique. Iraqi J Sci 63(12):5106–5118CrossRef
22.
Mwafaq RK, Abbas AK, Abdullah LA (2022) Evaluation of PARP-1 by immunohistochemistry in a sample of Iraqi patients with gastric cancer. Iraqi J Sc 63(2):467–479CrossRef
23.
Zhang Y, Zhang S, Wang X et al (2012) Prognostic significance of FOXP1 as an oncogene in hepatocellular carcinoma. J Clin Pathol 65:528–533CrossRefPubMed
24.
SAS. Statistical Analysis System, User's Guide. Statistical. Version 9.1th ed. SAS. Inst. Inc 2012; Cary. N.C., p 41–52
25.
26.
Montazerabadi AR, Sazgarnia A, Bahreyni-Toosi MH et al (2012) Mitoxantrone as a prospective photosensitizer for photodynamic therapy of breast cancer. Photodiagnosis Photodyn Ther 9:46–51CrossRefPubMed
27.
Santos AF, Almeida DR, Terra LF et al (2019) Photodynamic therapy in cancer treatment - an update review. J Cancer Metastasis Treat 5:25
28.
Giatromanolaki A, Koukourakis MI, Sivridis E, Gatter KC, Harris AL, Banham AH (2006) Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1a expression. Modern Pathol 19(1):9–16CrossRef
29.
30.
Hu Z, Zhu L, Gao J et al (2015) Expression of FOXP1 in epithelial ovarian cancer (EOC) and its correlation with chemotherapy resistance and prognosis. Tumor Biol 36(9):7269–7275CrossRef
31.
Xiao J, He B, Zou Y et al (2016) Prognostic value of decreased FOXP1 protein expression in various tumors: a systematic review and meta-analysis. Sci Rep 6:30437CrossRefPubMedPubMedCentral
32.
Feng J, Zhang X, Zhu H, Wang X, Ni S, Huang J (2012) High expression of FoxP1 is associated with improved survival in patients with non–small cell lung cancer. Am J Clin Pathol 138:230–235CrossRefPubMed
33.
Silva PD, Garaud S, Solinas C et al (2019) FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer. EBio Med 39:226–238
34.
Fox SB, Brown P, Han C et al (2004) Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas. Clin Cancer Res 10:3521–3527CrossRefPubMed
35.
Bates GJ, Fox SB, Han C et al (2008) Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas. Breast Cancer Res Treat 111:453–459CrossRefPubMed
36.
Giatromanolaki A, Koukourakis MI, Sivridis E et al (2006) Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1α expression. Mod Pathol 19:9–16CrossRefPubMed
37.
Gheghiani L, Shang S, Fu Z (2020) Targeting the PLK1-FOXP1 pathway as a novel therapeutic approach for treating advanced prostate cancer. Sci Rep 10:12327CrossRefPubMedPubMedCentral
38.
Kim MM, Darafsheh A (2020) Light sources and dosimetry techniques for photodynamic therapy. Photochem Photobiol 96(2):280–294CrossRefPubMed
39.
Ani C, Danyuo Y, Odusanya O, Soboyejo W (2018) Computational modeling of drug diffusion and inductive heating in an implantable biomedical device for localized thermo-chemotherapy of cancer cells/tissue. Cogent Eng 5:1463814CrossRef
40.
Ashkbar A, Rezaei F, Attari F, Ashkevarian S (2020) Treatment of breast cancer in vivo by dual photodynamic and photothermal approaches with the aid of curcumin photosensitizer and magnetic nanoparticles. Sci Rep 10:1–12CrossRef
41.
Kabiri S, Rezaei F (2022) Liver cancer treatment with integration of laser emission and microwave irradiation with the aid of gold nanoparticles. Sci Rep 12:9271CrossRefPubMedPubMedCentral
42.
Shukla R, Chanda N, Zambre A et al (2012) Laminin receptor specifc therapeutic gold nanoparticles (198AuNP-EGCg) show efficacy in treating prostate cancer. Proc Nati Acad Sci 109:12426–12431CrossRef
43.
Metadata
Title
Immunohistochemistry technique for effect of gold nanoparticles, laser, and photodynamic therapy on FoxP1 level in infected mice with mammary adenocarcinoma
Authors
Sumaiah I. Hussein
Amal Y. Al-Yasiri
Heba F. Hassan
Basim M. Kashman
Rasha A. Azeez
Publication date
01-12-2023
Publisher
Springer London
Published in
Lasers in Medical Science / Issue 1/2023
Print ISSN: 0268-8921
Electronic ISSN: 1435-604X
DOI
https://doi.org/10.1007/s10103-023-03765-7

Other articles of this Issue 1/2023

Lasers in Medical Science 1/2023 Go to the issue

Original Article

The effects of low-level laser therapy on polycystic ovarian syndrome in rats: three different dosages

Original Article

Micro-CT analysis and leakage of bioceramic retrofillings after ultrasonic and Er:YAG laser cavity preparations: an in vitro study

Original Article

Needle-free electronically controlled jet injection with corticosteroids in recalcitrant keloid scars: a retrospective study and patient survey

Original Article

Effect of various Er:YAG laser conditioning energies on dentin surface: micromorphological investigation and dentin-resin shear bond strength test

Original Article

Numerical investigation of a novel method of laser assisted cryopreservation of biological tissue considering non-fourier heat conduction

Review Article

Effectiveness of laser and topical tranexamic acid combination therapy in melasma: An updated systematic review and meta-analysis of randomized controlled trials